Desde el departamento de Información Médica te ofrecemos un nuevo formato para mantenerte actualizado sobre nuestros estudios de forma ágil y rápida. A continuación, podrás escuchar un resumen de los siguientes estudios a través de estos podcasts de 2/3 minutos de duración.
Empagliflozin in Patients with Chronic Kidney Disease
EPISODIO 1
Estudio EMPA-KIDNEY
- The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022. doi: 10.1056/NEJMoa2204233.
- EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022. 37(7):1317-1329.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
- Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018;11(6):749-761.
Empagliflozin in Patients Hospitalized for Acute Heart Failure
EPISODIO 2
Estudio EMPULSE
- Tromp J, Ponikowski P, Salsali A, et al. Sodium–glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826-834.
- Voors AA, Angermann CE, Teerlink JR, et al. Efficacy and safety of empagliflozin in hospitalized heart failure patients: Main results from the EMPULSE Trial. Abstract and oral presentation at the American Heart Association Scientific Sessions 2021; November 13–15, 2021.
- Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11(4):329-337.
- Setoguchi S, Warner Stevenson L, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260-266.
Empagliflozin, cardiovascular outcomes, and mortatily in type 2 diabetes
EPISODIO 3
Estudio EMPA-REG OUTCOME
- Zinman B, Inzucchi S, Lachin J, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014;13:102.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Supplementary material. N Engl J Med. 2015;373(22):2117–2128.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. Supplementary material. N Engl J Med. 2016;375(4):323-334
Empagliflozin in heart failure with a reduced ejection fraction
EPISODIO 4
Estudio EMPEROR-REDUCED
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.
- Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019;21(10):1270-1278.
- Butler J, Anker SD, Filippatos G, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(13):1203-1212.
Empagliflozin in heart failure with a preserved ejection fraction
EPISODIO 5
Estudio EMPEROR-PRESERVED
- Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. Eur J Heart Fail. 2019;21(10):1270–1278.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
- Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved trial. Eur J Heart Fail. 2019;21(10):1279–1287.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461.
MI0011.092024